利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

15 条记录 (耗时 0.031 秒)

    Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
    2.
    发明授权
    Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis 失效
    使用抗菌蛋白和肽治疗中耳炎和鼻旁窦炎

    公开(公告)号：US06716813B2

    公开(公告)日：2004-04-06

    申请号：US09998547

    申请日：2001-11-27

    申请人： David J. Lim ,  Haa-Yung Lee ,  Paul Webster ,  Ali Andalibi ,  Jian-Dong Li ,  Tomas Ganz

    发明人： David J. Lim ,  Haa-Yung Lee ,  Paul Webster ,  Ali Andalibi ,  Jian-Dong Li ,  Tomas Ganz

    IPC分类号： A61K3800

    CPC分类号： A61K38/40 ,  A61K38/1729 ,  A61K38/47 ,  A61K2300/00

    摘要： Disclosed herein is a method for the treatment of otitis media and paranasal sinusitis using human defensins, lysozyme and/or lactoferrin as a new class of non-antibiotic antimicrobials. From studies of otitis media and paranasal sinusitis, it was observed that certain innate immune modulators were important in the bodies response to the infection. Therefore, these innate immune modulators, lysozyme, lactoferrin and defensins, were tested for use as a non-antibiotic treatment for infection, particularly infections such as otitis media and sinusitis.

    摘要翻译： 本文公开了一种使用人防御素，溶菌酶和/或乳铁蛋白作为新一类非抗生素抗微生物剂治疗中耳炎和鼻旁窦炎的方法。 从中耳炎和鼻旁窦炎的研究中，观察到某些先天免疫调节剂在身体对感染的反应中是重要的。 因此，这些先天免疫调节剂，溶菌酶，乳铁蛋白和防御素被测试用作感染的非抗生素治疗，特别是诸如中耳炎和鼻窦炎的感染。

    Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin
    9.
    发明授权
    Competitive regulation of hepcidin mRNA by soluble and cell-associated hemojuvelin 有权
    通过可溶性和细胞相关的血红蛋白的铁调素mRNA的竞争性调节

    公开(公告)号：US07745407B2

    公开(公告)日：2010-06-29

    申请号：US12397589

    申请日：2009-03-04

    申请人： Tomas Ganz ,  Lan Lin ,  Yigal P. Goldberg

    发明人： Tomas Ganz ,  Lan Lin ,  Yigal P. Goldberg

    IPC分类号： C12Q1/68 ,  A61K38/00

    CPC分类号： A61K38/1709

    摘要： Disclosed herein are hemojuvelin-specific siRNAs that vary hemojuvelin mRNA concentration. Also disclosed herein, GPI-hemojuvelin positively regulated hepcidin mRNA expression, independently of the IL-6 pathway, whereas soluble hemojuvelin (s-hemojuvelin) suppressed hepcidin mRNA expression in primary human hepatocytes in a log-linear dosedependent manner. Disclosed are compositions and methods for modulating diseases of iron metabolism and hepcidin expression or hepcidin levels.

    摘要翻译： 本文公开了改变hemojuvelin mRNA浓度的hemojuvelin特异性siRNA。 本文还公开了GPI-hemojuvelin与IL-6途径无关地正调节hepcidin mRNA表达，而可溶性hemojuvelin（s-hemojuvelin）以对数线性依赖方式抑制原代人肝细胞中的铁调素mRNA表达。 公开了用于调节铁代谢和铁调素表达或铁调素水平的疾病的组合物和方法。